Stockholm - Free Realtime Quote SEK

Respiratorius AB (RESP.ST)

Compare
0.0526 -0.0052 (-9.00%)
As of 4:44 PM GMT+2. Market Open.

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
NameTitlePayExercisedYear Born
Mr. Johan Drott Ph.D. CEO, President & Director -- -- 1966

Respiratorius AB

Medicon Village
Scheelevagen 2
Lund, 223 81
Sweden
46 7 09 22 41 40 https://www.respiratorius.com
Sector:?
Healthcare
Industry:?
Biotechnology

Description

Respiratorius AB (publ), a research company, develops drug candidates for the treatment of cancer, chronic obstructive pulmonary disease (COPD), and asthma. The company's products under development include VAL001, which has completed Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden.

Corporate Governance

Respiratorius AB’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers